Purinergic P2Y Receptor Antagonists
"Purinergic P2Y Receptor Antagonists" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Compounds that bind to and block the stimulation of PURINERGIC P2Y RECEPTORS. Included under this heading are antagonists for specific P2Y receptor subtypes.
| Descriptor ID |
D058921
|
| MeSH Number(s) |
D27.505.519.625.725.400.200.200 D27.505.696.577.725.400.200.200
|
| Concept/Terms |
Purinergic P2Y12 Receptor Antagonists- Purinergic P2Y12 Receptor Antagonists
- P2Y12 Receptor Antagonists
- Antagonists, P2Y12 Receptor
- Receptor Antagonists, P2Y12
- P2Y12 Purinoceptor Antagonists
- Antagonists, P2Y12 Purinoceptor
- Purinoceptor Antagonists, P2Y12
|
Below are MeSH descriptors whose meaning is more general than "Purinergic P2Y Receptor Antagonists".
Below are MeSH descriptors whose meaning is more specific than "Purinergic P2Y Receptor Antagonists".
This graph shows the total number of publications written about "Purinergic P2Y Receptor Antagonists" by people in this website by year, and whether "Purinergic P2Y Receptor Antagonists" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2012 | 0 | 1 | 1 |
| 2013 | 1 | 1 | 2 |
| 2014 | 2 | 1 | 3 |
| 2015 | 1 | 1 | 2 |
| 2016 | 1 | 2 | 3 |
| 2018 | 4 | 1 | 5 |
| 2019 | 0 | 3 | 3 |
| 2020 | 1 | 3 | 4 |
| 2021 | 2 | 2 | 4 |
| 2022 | 3 | 1 | 4 |
| 2024 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Purinergic P2Y Receptor Antagonists" by people in Profiles.
-
Aspirin vs P2Y12 Inhibitors: A Few Questions Unanswered. J Am Coll Cardiol. 2024 Jan 02; 83(1):e7.
-
A Comprehensive Review of the Pleiotropic Effects of Ticagrelor. Cardiovasc Drugs Ther. 2024 Aug; 38(4):775-797.
-
The Cost of Breaking Even: a Perspective on the Net Clinical Impact of Adding Aspirin to Antithrombotic Therapies in Patients with Atrial Fibrillation Undergoing Percutaneous Coronary Intervention. Cardiovasc Drugs Ther. 2024 Jun; 38(3):605-619.
-
Multifaceted Intervention to Improve P2Y12 Inhibitor Adherence After Percutaneous Coronary Intervention: A Stepped Wedge?Trial. J Am Heart Assoc. 2022 07 05; 11(13):e024342.
-
Effect of Genotype-Guided Oral P2Y12 Inhibitor Selection After Percutaneous Coronary Intervention: A Systematic Review and Meta-Analysis of Randomized Clinical Trials. Cardiovasc Revasc Med. 2022 08; 41:115-121.
-
Cancer treatment resumption in patients with new-generation drug-eluting stents. Coron Artery Dis. 2021 Jun 01; 32(4):295-301.
-
Efficacy and safety of prasugrel and clopidogrel in st-segment elevation myocardial infarction in prehospital setting. Am J Emerg Med. 2022 03; 53:254-255.
-
Oral Antiplatelet Therapy After Acute Coronary Syndrome: A Review. JAMA. 2021 Apr 20; 325(15):1545-1555.
-
Efficacy and safety of ticagrelor use in pre-hospital setting. Am J Emerg Med. 2022 02; 52:265-266.
-
Oral Antiplatelet Therapy Administered Upstream to Patients With NSTEMI. Crit Pathw Cardiol. 2020 12; 19(4):166-172.